Related Experiment Video
Updated: Aug 11, 2026
Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis
Published on: December 21, 2014
Heart-lung and lung transplantation for cystic fibrosis
N Lewiston1, V Starnes, J Theodore
1Department of Pediatrics, Stanford University School of Medicine, Children's Hospital, Palo Alto, CA 94304.
Insights
Lung transplantation is a viable option for end-stage Cystic Fibrosis (CF) patients, showing comparable outcomes to other conditions. However, specific postoperative challenges and resource limitations impact its widespread application.
Area of Science:
- Pulmonology
- Transplant Surgery
- Medical Genetics
Background:
- End-stage lung disease in Cystic Fibrosis (CF) necessitates advanced treatment options.
- Heart-lung or double lung transplantation is increasingly indicated for CF patients with severe pulmonary compromise.
Purpose of the Study:
- To evaluate the outcomes and specific postoperative challenges of lung transplantation in Cystic Fibrosis patients.
- To identify factors influencing the success and limitations of this procedure in the CF population.
Main Methods:
- Analysis of surgical outcomes for approximately 50 Cystic Fibrosis patients undergoing heart-lung or double lung transplantation in the US and Europe.
- Review of specific postoperative complications and management strategies relevant to the CF diagnosis.
Main Results:
- Transplantation outcomes for CF patients are comparable to those with other underlying diseases.
- Specific postoperative issues include higher cyclosporine dosages, diabetes risk with corticosteroids, sinus pathogen threats, increased organ toxicity, and psychological adjustment.
- Improved postoperative management may reduce mortality and morbidity.
Conclusions:
- Lung transplantation offers comparable results for end-stage Cystic Fibrosis lung disease but presents unique postoperative challenges.
- Scarcity of donor organs and high procedure costs limit the overall impact on the broader CF population.
- Further advancements in postoperative care are crucial for optimizing outcomes.
Abstract:
End-stage lung disease in Cystic Fibrosis (CF) now is considered to be one of the indications for heart-lung or double lung transplantation. Results of this surgery for 50 or so CF patients in the US and Europe are about the same as for other diseases, although there are some postoperative problems specific for this diagnosis. These include: need for higher oral dosages of cyclosporine, likelihood of precipitation of diabetes mellitus with high dosage corticosteroid therapy for acute lung rejection, constant threat of pathogens remaining in the sinuses, increased likelihood of drug toxicity to the liver and kidneys, and need to make a psychological transition from a patient with a fatal disease to one with optimism about the future. Although improved postoperative management likely will improve postoperative mortality and morbidity, scarcity of donor organs and the high cost of the procedure will limit the impact of this procedure on the general CF population.
